Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2015 | Recent developments in targeted therapies for chronic lymphocytic leukemia

Jacqueline Barrientos • 2 Jun 2015
ASCO 2015
Chronic Lymphocytic Leukemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, provides a summary of recent developments in new therapeutic options for patients with chronic lymphocytic leukemia (CLL), including those with known complications, such as the presence of 17p deletion.

More from Jacqueline Barrientos

Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL 5:35
Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL
Jacqueline Barrientos • 19 Jun 2025
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors 2:18
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
Jacqueline Barrientos • 19 Jun 2025
Understanding mechanisms of resistance to BTK and BCL2 inhibitors in patients with CLL 3:47
Understanding mechanisms of resistance to BTK and BCL2 inhibitors in patients with CLL
Jacqueline Barrientos • 19 Jun 2025
Uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL 11:33
Uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Jacqueline Barrientos • 19 Jun 2025

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals